Break from their own history: management says the current business no longer follows the company's own past pattern — fo
The model's full reasoning — Q2 2023 call → NOWe need to determine if management explicitly frames the current business as a departure from its own historical pattern, supported by concrete current facts. Let's review the transcript. Amir London says: "I'm pleased to report the strong start to 2023 continued in the second quarter, both financially and operationally. And we are well positioned to achieve our 2023 full year guidance... We achieved the top and bottom line growth anticipated in our business in the first six months of the year. Importantly, we continue to effectively leverage our multiple growth drivers, including a significant increase in KEDRAB sales and Kedrion for further distribution in the U.S., the portfolio of four FDA-approved hemogloblins acquired in late 2021: CYTOGAM, HEPAGAMB, VARIZIG and WINRHO and our Israeli distribution business." He mentions "significant increase in KEDRAB sales" but does he compare to own history? He says "During the first six months of this year, we experienced a significant increase in demand for the product in the U.S., and we anticipate even further momentum in the second half of the year that includes the summer months." That's a statement about current demand increase, but is it framed as a departure from historical pattern? He doesn't say "unlike anything we've seen before" or "strongest ever". He says "significant increase" but that could be just a good quarter. Also, he mentions "we continue to effectively leverage our multiple growth drivers" - that's routine. Later, he says: "As a reminder, this product continues to generate more than 50% gross margin for Kamada." That's not a pattern break. He also says: "Additionally, our U.S. team established during 2022 continues to achieve good progress in promoting our specialty immunoglobulin portfolio... We remain encouraged by the positive feedback received from key U.S. physicians who are seeking to publish new clinical data related to our products, while conducting educational symposium that we believe will have a positive impact on understanding of this medicine, contributing to continued growth in demand." That's about progress, not a break. He mentions the FDA approval for manufacturing CYTOGAM at Israeli facility, and Health Canada approval. That's a milestone, but not a pattern break in terms of business activity.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SFIX | Stitch Fix, Inc. | Q3 2024 | 2024-06-04 | C+ |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| STC | Stewart Information Services Corporation | Q1 2022 | 2022-04-29 | C+ |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| EGY | VAALCO Energy, Inc. | Q2 2021 | 2021-08-12 | B |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
PFIE · Q1 2023 → YESThe question is: Does management declare that what's happening RIGHT NOW is a POSITIVE DEPARTURE FROM THE COMPANY'S OWN HISTORICAL PATTERN, anchored in specific present-tense operating facts? YES Ryan Oviatt explicitly frames the current quarter as a departure from the company’s own history: “second highest revenue quarter ever,” “best quarterly net income and EBITDA in company history,” “eight quarters of sequential revenue growth,” and “three of the top five revenue quarters have all been within the last nine months … within the last nine months.” He anchors the break in concrete present-tense facts: “revenue from our legacy business for the prior six months exceeds our total revenue for all of 2021,” “Our share in this market has never been stronger,” and “We have now supported the integration of over 85, 000 burner management solutions.” Cameron Tidball reinforces the same point: “Q1 represented one of the strongest quarters in our history, surpassing our strong 2022 Q3 and Q4 results” and “eight consecutive quarters of top-line revenue growth.
DXCM · Q4 2023 → YESThe question is: Does management declare that what's happening RIGHT NOW is a POSITIVE DEPARTURE FROM THE COMPANY'S OWN HISTORICAL PATTERN, anchored in specific present-tense operating facts? YES Management explicitly frames 2023 as “one of the most transformational years in our company’s history” and states that the G7 launch “has completely changed the market landscape in the US” while noting the prescriber base expanded by ~40% and primary-care scripts now exceed 70% of new business. These characterizations are anchored in concrete, present-tense operating facts that occurred during the just-completed year (600 k new users, $1 B Q4 revenue, $1 B adjusted EBITDA, record free-cash-flow growth, doubled reimbursed population, fastest quarterly U.S. growth since early 2021).
ADSK · Q3 2019 → YESThe question is: Does management declare that what's happening RIGHT NOW is a POSITIVE DEPARTURE FROM THE COMPANY'S OWN HISTORICAL PATTERN, anchored in specific present-tense operating facts? YES Management explicitly frames the current quarter as a departure from their own recent history by declaring it “the highest growth quarter for both [ARR and ARPS] since we started our business model transition over four years ago.” They anchor the claim in concrete, present-tense operating facts already occurring in Q3: record growth 33% in total ARR, 17% ARPS increase, 143,000 subscription additions, 53,000 cloud subs, and the sum of revenue growth plus free-cash-flow margin reaching 32% “a level we have not seen for four years.